Novo agrees $2.6B deal for preclinical GLP-1/GIP drug from in-demand Hengrui

Fuente: FierceBiotech
Novo’s ongoing efforts to rejuvenate its pipeline have seen the Big Pharma turn to one of the most in-demand drug developers in China.
Volver